Կանադա - անգլերեն - Health Canada

teva canada limited - teriparatide (teriparatide acetate) - solution - 250mcg - teriparatide (teriparatide acetate) 250mcg - parathyroid agents

Իսրայել - անգլերեն - Ministry of Health

abic marketing ltd, israel - teriparatide as acetate - solution for injection - teriparatide as acetate 250 mcg/ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:teriparatide teva is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, teriparatide teva increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :teriparatide teva is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:teriparatide teva is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - teriparatide, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: glacial acetic acid; water for injections; sodium acetate; cresol; mannitol; hydrochloric acid; sodium hydroxide - teriparatide lupin is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. ,teriparatide lupin is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - teriparatide acetate 0.25 mg/ml - solution for injection - 250 mcg/ml - active: teriparatide acetate 0.25 mg/ml excipient: glacial acetic acid hydrochloric acid mannitol metacresol nitrogen sodium acetate trihydrate sodium hydroxide water for injection - in combination with calcium and vitamin d, for the treatment osteoporosis in postmenopausal women and in men at high risk of fracture.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - teriparatide sun is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).

Իսրայել - անգլերեն - Ministry of Health

kamada ltd, israel - teriparatide - solution for injection - teriparatide 0.250 mg / 1 ml - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fractureteriparatide kamada is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, teriparatide kamada increases bmd reduces the risk of vertebral and nonvertebral fractures.increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fractureteriparatide kamada is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fractureteriparatide kamada is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - teriparatide, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; sodium acetate; glacial acetic acid; cresol; hydrochloric acid; sodium hydroxide - teriparatide gh is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. ,teriparatide gh is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - teriparatide, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: mannitol; water for injections; glacial acetic acid; sodium acetate; cresol; hydrochloric acid; sodium hydroxide - teriparatide lapl is indicated for the treatment of osteoporosis in postmenopausal women and the treatment of primary osteoporosis in men when other agents are considered unsuitable and when there is a high risk of fractures. ,teriparatide lapl is indicated for the treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at high risk for fracture.

Ճապոնիա - անգլերեն - すりの適正使用協議会 RAD-AR Council, Japan

asahi kasei pharma corporation - teriparatide acetate - injection

Իռլանդիա - անգլերեն - HPRA (Health Products Regulatory Authority)

teva b.v. - teriparatide - solution for injection in pre-filled pen - 20/80 - parathyroid hormones and analogues; teriparatide